effects of amlodipine to reduce cardiac iron overload
- Conditions
- Major Thalasemia.Beta thalassemiaD56.1
- Registration Number
- IRCT20190829044642N1
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
1. All patients had informed consent to participate in the study.
2- All thalassemia major patients referring to Amir Kabir Hospital, Arak, over 5 years old.
.3. All healthy children without any underlying hematologic or hereditary diseases except major thalassemia
All patients who did not have informed consent to participate and continue to participate in the study.
All patients who will undergo a chelation therapy strategy during the 12 months of study due to changes.
All patients with advanced heart failure or Ef less than 30% or AV block
All patients with MRI contraindication
All patients with liver disorders, hepatitis B and C, HIV, any inflammation and renal failure
All patients who have complications with amlodipine include edema, hypotension, palpitations, etc
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac iron overload. Timepoint: Will be measured at baseline and 12 months after treatment. Method of measurement: T2*MRI.
- Secondary Outcome Measures
Name Time Method Ferritin serum level. Timepoint: At baseline and 1, 6, 12 months after treatment. Method of measurement: ELISA.